{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T23:33:07Z","timestamp":1769124787292,"version":"3.49.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T00:00:00Z","timestamp":1708473600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","celltherapyjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.jcyt.2024.02.010","type":"journal-article","created":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T17:48:40Z","timestamp":1708710520000},"page":"592-598","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Prognostic factors in haploidentical transplantation with post-transplant cyclophosphamide for acute myeloid leukemia"],"prefix":"10.1016","volume":"26","author":[{"given":"Sho","family":"Shibata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9662-5093","authenticated-orcid":false,"given":"Yasuyuki","family":"Arai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8959-6271","authenticated-orcid":false,"given":"Tadakazu","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shohei","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Yamasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Akasaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8661-3179","authenticated-orcid":false,"given":"Noriko","family":"Doki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuichi","family":"Ota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1410-0830","authenticated-orcid":false,"given":"Yumiko","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken-ichi","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Nagafuji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Eto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Ohigashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirohisa","family":"Nakamae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Onizuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4404-2870","authenticated-orcid":false,"given":"Yoshiko","family":"Atsuta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1602-9775","authenticated-orcid":false,"given":"Masamitsu","family":"Yanada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2024.02.010_bib0001","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1053\/bbmt.2002.v8.pm12171484","article-title":"Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide","volume":"8","author":"O'Donnell","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2024.02.010_bib0002","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2024.02.010_bib0003","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/j.bbmt.2012.06.019","volume":"18","author":"Solomon","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2024.02.010_bib0004","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.bbmt.2015.06.008","article-title":"HLA-haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide after busulfan-containing reduced-intensity conditioning","volume":"21","author":"Sugita","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2024.02.010_bib0005","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41409-018-0279-1","article-title":"Myeloablative and reduced-intensity conditioning in HLA-haploidentical peripheral blood stem cell transplantation using post-transplant cyclophosphamide","volume":"54","author":"Sugita","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2024.02.010_bib0006","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1001\/jamaoncol.2019.3541","article-title":"Haploidentical stem cell transplantation with posttransplant cyclophosphamide therapy vs other donor transplantations in adults with hematologic cancers: a systematic review and meta-analysis","volume":"5","author":"Gagelmann","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jcyt.2024.02.010_bib0007","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/nrclinonc.2015.128","article-title":"Modern approaches to HLA-haploidentical blood or marrow transplantation","volume":"13","author":"Kanakry","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jcyt.2024.02.010_bib0008","doi-asserted-by":"crossref","first-page":"111.e1","DOI":"10.1016\/j.jtct.2021.11.012","article-title":"Cytokine release syndrome following peripheral blood stem cell haploidentical hematopoietic cell transplantation with post-transplantation cyclophosphamide","volume":"28","author":"Otoukesh","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jcyt.2024.02.010_bib0009","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/hon.2772","article-title":"Cytokine release syndrome after allogeneic stem cell transplantation with posttransplant cyclophosphamide","volume":"38","author":"Sol\u00e1n","year":"2020","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.jcyt.2024.02.010_bib0010","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1182\/bloodadvances.2020003005","article-title":"Impaired T- and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide","volume":"5","author":"Rambaldi","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jcyt.2024.02.010_bib0011","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13045-022-01287-3","article-title":"Post-transplant cyclophosphamide alters immune signatures and leads to impaired T cell reconstitution in allogeneic hematopoietic stem cell transplant","volume":"15","author":"Zhao","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jcyt.2024.02.010_bib0012","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1532\/IJH97.06239","article-title":"Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP System","volume":"86","author":"Atsuta","year":"2007","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jcyt.2024.02.010_bib0013","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12185-015-1894-x","article-title":"Introduction of Transplant Registry Unified Management Program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data)","volume":"103","author":"Atsuta","year":"2016","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jcyt.2024.02.010_bib0014","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","article-title":"Estimation of failure probabilities in the presence of competing risks: new representations of old estimators","volume":"18","author":"Gooley","year":"1999","journal-title":"Stat Med"},{"key":"10.1016\/j.jcyt.2024.02.010_bib0015","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","article-title":"A class of K-sample tests for comparing the cumulative incidence of a competing risk","volume":"16","author":"Gray","year":"1988","journal-title":"Ann Stat"},{"key":"10.1016\/j.jcyt.2024.02.010_bib0016","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.02.010_bib0017","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1080\/10428194.2017.1357173","article-title":"Effect of cytogenetic risk status on outcomes for patients with acute myeloid leukemia undergoing various types of allogeneic hematopoietic cell transplantation: an analysis of 7812 patients","volume":"59","author":"Yanada","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jcyt.2024.02.010_bib0018","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4","article-title":"Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors","volume":"15","author":"Harrell","year":"1996","journal-title":"Stat Med"},{"key":"10.1016\/j.jcyt.2024.02.010_bib0019","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2024.02.010_bib0020","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1007\/s00277-019-03669-z","article-title":"The prognostic impact of the cytomegalovirus serostatus in patients with chronic hematological malignancies after allogeneic hematopoietic stem cell transplantation: a report from the Infectious Diseases Working Party of EBMT","volume":"98","author":"Schmidt-Hieber","year":"2019","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jcyt.2024.02.010_bib0021","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1182\/blood-2013-05-499830","article-title":"CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT","volume":"122","author":"Schmidt-Hieber","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.02.010_bib0022","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/s41409-023-01944-2","article-title":"CMV-IgG pre-allogeneic hematopoietic stem cell transplantation and the risk for CMV reactivation and mortality","volume":"58","author":"Eberhardt","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2024.02.010_bib0023","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1182\/blood.V95.7.2240","article-title":"Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation","volume":"95","author":"Broers","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.02.010_bib0024","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1182\/blood.V97.6.1572","article-title":"Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome","volume":"97","author":"Cornelissen","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.02.010_bib0025","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1182\/blood.2020009362","article-title":"Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis","volume":"137","author":"Goldsmith","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.02.010_bib0026","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/sj.bmt.1703927","article-title":"Pre-emptive treatment of CMV DNAemia in paediatric stem cell transplantation: the impact of recipient and donor CMV serostatus on the incidence of CMV disease and CMV-related mortality","volume":"31","author":"Matthes-Martin","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2024.02.010_bib0027","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s12185-010-0597-6","article-title":"Immune reconstitution and cytomegalovirus infection after allogeneic stem cell transplantation: the important impact of in vivo T cell depletion","volume":"91","author":"Schmidt-Hieber","year":"2010","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jcyt.2024.02.010_bib0028","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jmii.2015.07.011","article-title":"Risk factors and outcomes of cytomegalovirus viremia in pediatric hematopoietic stem cell transplantation patients","volume":"50","author":"Wu","year":"2017","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jcyt.2024.02.010_bib0029","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1007\/s00277-020-04051-0","article-title":"Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia conducted in Japan during the past quarter century","volume":"99","author":"Yanada","year":"2020","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jcyt.2024.02.010_bib0030","doi-asserted-by":"crossref","first-page":"4715","DOI":"10.1002\/cncr.24531","article-title":"Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis","volume":"115","author":"Gratwohl","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.jcyt.2024.02.010_bib0031","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1016\/j.bbmt.2018.06.026","article-title":"Relative impact of HLA matching and Non-HLA donor characteristics on outcomes of allogeneic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome","volume":"24","author":"Ayuk","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2024.02.010_bib0032","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/bmt.2011.110","article-title":"The EBMT risk score","volume":"47","author":"Gratwohl","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2024.02.010_bib0033","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1182\/blood-2014-11-613323","article-title":"Allogeneic HY antibodies detected 3 months after female-to-male HCT predict chronic GVHD and nonrelapse mortality in humans","volume":"125","author":"Nakasone","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.02.010_bib0034","doi-asserted-by":"crossref","first-page":"e314","DOI":"10.3324\/haematol.2018.199646","article-title":"A confirmation of chronic graft-versus-host disease prediction using allogeneic HY antibodies following sex-mismatched hematopoietic cell transplantation","volume":"104","author":"Paul","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.jcyt.2024.02.010_bib0035","doi-asserted-by":"crossref","first-page":"7166","DOI":"10.1038\/s41598-023-34442-y","article-title":"Impact of anti-thymocyte globulin on survival outcomes in female-to-male allogeneic hematopoietic stem cell transplantation","volume":"13","author":"Tamaki","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcyt.2024.02.010_bib0036","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.3324\/haematol.2015.125294","article-title":"Risks and benefits of sex-mismatched hematopoietic cell transplantation differ according to conditioning strategy","volume":"100","author":"Nakasone","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.jcyt.2024.02.010_bib0037","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1182\/bloodadvances.2021006456","article-title":"Deletion of Y chromosome before allogeneic hematopoietic stem cell transplantation in male recipients with female donors","volume":"6","author":"Tamaki","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jcyt.2024.02.010_bib0038","doi-asserted-by":"crossref","first-page":"784.e1","DOI":"10.1016\/j.jtct.2021.06.012","article-title":"Female sex is associated with improved long-term survival following allogeneic hematopoietic stem cell transplantation","volume":"27","author":"Islam","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jcyt.2024.02.010_bib0039","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.3324\/haematol.2016.147645","article-title":"Donor and recipient sex in allogeneic stem cell transplantation: what really matters","volume":"101","author":"Kim","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.jcyt.2024.02.010_bib0040","doi-asserted-by":"crossref","first-page":"7194","DOI":"10.1002\/cam4.4262","article-title":"Impact of allogeneic stem cell transplantation comorbidity indexes after haplotransplant using post-transplant cyclophosphamide","volume":"10","author":"Jullien","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.jcyt.2024.02.010_bib0041","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N Engl J Med"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324924000574?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324924000574?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T09:31:54Z","timestamp":1716370314000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324924000574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S1465324924000574"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2024.02.010","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic factors in haploidentical transplantation with post-transplant cyclophosphamide for acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2024.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society for Cell & Gene Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}